Schizophrenia remains one of the most devastating illnesses known to man: not only does it commonly strike young people at the threshold of their productive life, but its deteriorating, relapsing course over many years results in great emotional and financial cost to patients, carers and society at large. The introduction of the first antipsychotics raised hopes that we would be able to cure this terrible disorder; however, time has shown that, although effective against the positive symptoms of the disorder, the first-generation antipsychotics do very little to relieve other symptoms of schizophrenia and often exacerbate some of them.
Furthermore, these medications produce a range of side-effects that are not only uncomfortable for the patient but also potentially dangerous, certainly stigmatising, and often resulting in noncompliance with treatment. 1 It should be self-evident to anyone who has worked with patients who suffer from schizophrenia that the treatment of this illness is a complex, multimodal endeavour that is unlikely ever to consist of a single type of intervention, whether pharmacological or otherwise. They will also know that addressing the positive, negative and cognitive symptoms of the disorder as well as the treatment resistance that occurs in many patients requires the concerted effort of a number of different health professionals and allied health professionals. Nonetheless, pharmacological treatment remains the cornerstone of treatment without which the rest of the interventions will largely be in vain. Therefore, before we can address all the other issues involved in the treatment of schizophrenia, we must first ensure optimal pharmacological treatment.
In the past two decades, psychiatrists have become progressively more aware of the importance of early, effective and sustained intervention in the treatment of schizophrenia. 2 There is good evidence today to show that intervention in the early phases of schizophrenia will prevent further functional deterioration and that a majority of patients will achieve good outcome, at least in the short term. Over the longer term, the picture is considerably less encouraging -almost all patients will relapse within 5 years, and the principal reason for this will be non-compliance with predecessors, and they also improved aspects of the disorder that could not be addressed adequately before. However, the vast improvement in compliance that was expected did not materialise -although compliance with second-generation antipsychotics certainly is better than it was with the first-generation medications, there is still a high rate of treatment recidivism, with the result that medication discontinuation still occurs at an unacceptably high rate. 3 There is therefore the risk that the clinical advantages that may be attained with the second-generation antipsychotics will be negated by poor compliance. Simply put, the medication cannot work if the patient does not take it.
One of the strategies to improve treatment compliance Absolute medication compliance has therefore become a more realistic goal for many patients.
Risperidone long-acting injection (RLAI) has been proven to be effective and safe in a number of studies in subjects with recurrent schizophrenia; 5, 6 however, a most significant development has been the use of this compound in subjects with first episodes of psychosis. 7 The use of a long-acting, intramuscular formulation of an antipsychotic medication in subjects with first onset of psychosis seems counter-intuitive, but when we stop to evaluate the arguments surrounding the issue, I believe that the prejudice against such a treatment modality can be overcome.
Many clinicians who have worked with psychiatric disorders over long periods still seem to fail to recognise the fact that patients with schizophrenia, and in particular those in the early phases of the disease, face many obstacles to compliance: they are often bewildered and paranoid, and may have been admitted and treated against their will. They do not understand why they had to come to hospital and why they had to get treatment. It takes many months and even years for healthy individuals to come to understand the complexities of psychiatric disorders -in fact many so-called healthy people and societies never reach that
goal -yet we expect our patients to attain it during the brief and chaotic time of their first admission to hospital. We expect them to use their logical brain to integrate all the information, yet it is this very logical brain that is dysfunctional during the psychotic illness! Furthermore, families are often divided in their level of insight and commitment, and it is not uncommon for family members to be ambivalent about treatment. Also, family members often harbour anger towards and fear of the patient, due to sometimes traumatic months and years that precede the first admission, and are therefore either afraid to put pressure on the subject or unwilling to because of resentment. Because they do not have the privilege of years of experience like we do, they find it difficult to grasp the importance of sustained treatment over long periods of time.
We now have robust evidence that untreated psychosis is detrimental to the brain and to the long-term outcome of schizophrenia. We also know that poor compliance is a very real problem in this patient population. No effort should therefore be spared to improve compliance and thereby prevent the 'toxic' effects of psychosis on the brain. A long-acting, injectable formulation of an atypical antipsychotic is probably one of the best pharmacological tools that we have available at this point. At the very least it will provide patients and doctors with an additional treatment option to those currently available, but in the ideal situation a patient in the early phases of illness will start on this medication and, if effective, maintain treatment for the full prescribed period, ensuring the best possible outcome that modern psychiatry can provide. Long-acting, injectable risperidone is clearly a step forward in the evolution of antipsychotic medications.
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